Characterization of anticancer drug resistance by reverse-phase protein array: new targets and strategies.
BRAF inhibitor
PARP inhibitor
Proteomics
RPPA
adaptive resistance
drug resistance
immune checkpoint inhibitor
precision oncology
reverse-phase protein array
Journal
Expert review of proteomics
ISSN: 1744-8387
Titre abrégé: Expert Rev Proteomics
Pays: England
ID NLM: 101223548
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
pubmed:
26
4
2022
medline:
9
6
2022
entrez:
25
4
2022
Statut:
ppublish
Résumé
Drug resistance is the main barrier to achieving cancer cures with medical therapy. Cancer drug resistance occurs, in part, due to adaptation of the tumor and microenvironment to therapeutic stress at a proteomic level. Reverse-phase protein arrays (RPPA) are well suited to proteomic analysis of drug resistance due to high sample throughput, sensitive detection of phosphoproteins, and validation for a large number of critical cellular pathways. This review summarizes contributions of RPPA to understanding and combating drug resistance. In particular, contributions of RPPA to understanding resistance to PARP inhibitors, BRAF inhibitors, immune checkpoint inhibitors, and breast cancer investigational therapies are discussed. Articles reviewed were identified by MEDLINE, Scopus, and Cochrane search for keywords 'proteomics,' 'reverse-phase protein array,' 'drug resistance,' 'PARP inhibitor,' 'BRAF inhibitor,' 'immune checkpoint inhibitor,' and 'I-SPY' spanning October 1, 1960 - October 1, 2021. Precision oncology has thus far failed to convert the armament of targeted therapies into durable responses for most patients, highlighting that genetic sequencing alone is insufficient to guide therapy selection and overcome drug resistance. Combined genomic and proteomic analyses paired with creative drug combinations and dosing strategies hold promise for maturing precision oncology into an era of improved patient outcomes.
Identifiants
pubmed: 35466854
doi: 10.1080/14789450.2022.2070065
pmc: PMC9215307
mid: NIHMS1800725
doi:
Substances chimiques
Antineoplastic Agents
0
Protein Kinase Inhibitors
0
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
115-129Subventions
Organisme : NCI NIH HHS
ID : U01 CA253472
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA217685
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA210950
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA217842
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA209851
Pays : United States
Organisme : NCI NIH HHS
ID : R50 CA221675
Pays : United States
Références
Obstet Gynecol. 2018 Sep;132(3):545-554
pubmed: 30095787
Nat Commun. 2020 Jul 24;11(1):3726
pubmed: 32709856
Cell. 2017 Feb 9;168(4):707-723
pubmed: 28187290
Oncogene. 2021 Sep;40(37):5590-5599
pubmed: 34304249
N Engl J Med. 2012 Dec 13;367(24):2316-21
pubmed: 23134356
Front Immunol. 2019 Nov 14;10:2657
pubmed: 31798587
Cancer Discov. 2012 Sep;2(9):798-811
pubmed: 22961666
J Clin Oncol. 2019 Nov 10;37(32):2968-2973
pubmed: 31173551
Cancer Cell. 2003 Apr;3(4):317-25
pubmed: 12726858
Clin Pharmacol Ther. 2009 Jul;86(1):97-100
pubmed: 19440188
Oncotarget. 2017 Dec 24;9(9):8206-8222
pubmed: 29492189
Elife. 2018 Jul 11;7:
pubmed: 29993362
Science. 2017 Mar 17;355(6330):1152-1158
pubmed: 28302823
Lancet. 2017 Oct 28;390(10106):1949-1961
pubmed: 28916367
J Clin Invest. 2020 Nov 2;130(11):5951-5966
pubmed: 33016929
NPJ Breast Cancer. 2017 Aug 25;3:31
pubmed: 28948212
Clin Cancer Res. 2020 Nov 15;26(22):6039-6050
pubmed: 32820016
Cancers (Basel). 2019 May 29;11(6):
pubmed: 31146482
Cancer Res. 2021 May 15;81(10):2774-2787
pubmed: 33514515
Nature. 2016 May 25;534(7605):55-62
pubmed: 27251275
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Cell. 2010 Apr 2;141(1):69-80
pubmed: 20371346
Mol Cell Proteomics. 2005 Apr;4(4):377-83
pubmed: 15671041
JAMA Oncol. 2016 Nov 01;2(11):1452-1459
pubmed: 27273579
Proteome Sci. 2012 Sep 24;10(1):56
pubmed: 23006314
Methods Enzymol. 2020;635:1-20
pubmed: 32122539
Clin Cancer Res. 2012 Dec 1;18(23):6426-35
pubmed: 23045247
Cancer Discov. 2012 Nov;2(11):1048-63
pubmed: 22915751
Mol Cell Proteomics. 2018 Aug;17(8):1515-1530
pubmed: 29716986
Methods Mol Biol. 2011;723:275-301
pubmed: 21370072
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
Nature. 2012 Jun 28;486(7404):537-40
pubmed: 22722843
Cell Rep. 2017 Nov 14;21(7):1953-1967
pubmed: 29141225
J Clin Oncol. 2005 May 20;23(15):3614-21
pubmed: 15908672
N Engl J Med. 2016 Jul 7;375(1):23-34
pubmed: 27406347
Nature. 2019 Nov;575(7782):299-309
pubmed: 31723286
Nat Genet. 2013 Dec;45(12):1446-51
pubmed: 24185510
Cancer Cell. 2018 Mar 12;33(3):401-416.e8
pubmed: 29533782
J Invest Dermatol. 2021 Jan;141(1):23-31
pubmed: 32268150
Nat Rev Drug Discov. 2021 Dec;20(12):899-919
pubmed: 33686237
Oncogene. 2001 Apr 12;20(16):1981-9
pubmed: 11360182
Cell. 2018 Aug 9;174(4):968-981.e15
pubmed: 30078711
Cancer Treat Rev. 2016 Feb;43:50-7
pubmed: 26827692
J Clin Invest. 2015 Apr;125(4):1459-70
pubmed: 25705882
NPJ Breast Cancer. 2021 Oct 5;7(1):131
pubmed: 34611148
NPJ Breast Cancer. 2020 Oct 2;6:48
pubmed: 33083527
Proteomics. 2003 Nov;3(11):2085-90
pubmed: 14595806
Clin Cancer Res. 2021 Dec 1;27(23):6354-6365
pubmed: 34518313
Bioinformatics. 2015 Mar 15;31(6):912-8
pubmed: 25380958
Sci Transl Med. 2017 May 31;9(392):
pubmed: 28566428
Nat Commun. 2020 Jan 7;11(1):8
pubmed: 31911630
Oncologist. 2020 Jan;25(1):e160-e169
pubmed: 31395751
Nat Commun. 2018 Feb 21;9(1):746
pubmed: 29467415
Cell. 2016 Jul 28;166(3):755-765
pubmed: 27372738
Nat Cancer. 2021 Jan;2(1):66-82
pubmed: 33738458
Adv Exp Med Biol. 2019;1188:95-111
pubmed: 31820385
Nature. 2017 Oct 5;550(7674):133-136
pubmed: 28953887
Biotechniques. 2012 Sep;0(0):1-7
pubmed: 22946677
Nature. 2018 Aug;560(7718):382-386
pubmed: 30089911
N Engl J Med. 2011 Jun 30;364(26):2507-16
pubmed: 21639808
Nat Genet. 2013 Dec;45(12):1439-45
pubmed: 24185512
Cancer Discov. 2019 Feb;9(2):210-219
pubmed: 30425037
Bioinformatics. 2009 Jun 1;25(11):1384-9
pubmed: 19336447
Bioinformatics. 2009 Mar 1;25(5):650-4
pubmed: 19176552
PLoS One. 2013 Jun 24;8(6):e66755
pubmed: 23826126
Mol Cell Proteomics. 2014 Jul;13(7):1690-704
pubmed: 24719451
Methods Mol Biol. 2016;1362:77-89
pubmed: 26519170
Nat Commun. 2020 May 14;11(1):2393
pubmed: 32409712
Nat Rev Cancer. 2020 Dec;20(12):743-756
pubmed: 33033407
Crit Rev Oncol Hematol. 2021 Jun;162:103351
pubmed: 33989769
N Engl J Med. 2015 Jan 1;372(1):30-9
pubmed: 25399551
Nature. 2002 Jun 27;417(6892):949-54
pubmed: 12068308
N Engl J Med. 2012 Apr 12;366(15):1382-92
pubmed: 22452356
Methods Mol Biol. 2011;785:345-61
pubmed: 21901611
Nat Commun. 2020 Mar 19;11(1):1459
pubmed: 32193378
Proc Natl Acad Sci U S A. 2014 Nov 11;111(45):15964-8
pubmed: 25349424
JCO Precis Oncol. 2018 Aug 16;2:
pubmed: 32914002
Mol Cell Proteomics. 2019 Sep;18(9):1893-1898
pubmed: 31308250
Nat Commun. 2021 Nov 5;12(1):6428
pubmed: 34741023
Cell. 2015 Jun 18;161(7):1681-96
pubmed: 26091043
Lancet Oncol. 2019 Apr;20(4):570-580
pubmed: 30880072
Sci Transl Med. 2016 Oct 26;8(362):362ps17
pubmed: 27797957
JAMA Netw Open. 2019 May 3;2(5):e192535
pubmed: 31050774
Clin Cancer Res. 2016 Apr 1;22(7):1592-602
pubmed: 26673799
Cancer Res. 2013 Dec 1;73(23):6856-64
pubmed: 24217577
JCO Precis Oncol. 2018 Sep 13;2:
pubmed: 32913986
Nat Med. 2018 May;24(5):556-562
pubmed: 29736026
Br J Cancer. 2018 Jan;118(1):9-16
pubmed: 29319049
Clin Cancer Res. 2014 Apr 1;20(7):1757-1767
pubmed: 24398047
Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9330-5
pubmed: 12876202
Nat Biotechnol. 2020 May;38(5):586-599
pubmed: 32393914
Expert Rev Proteomics. 2019 Oct;16(10):841-850
pubmed: 31512530
Biochem Soc Trans. 2014 Aug;42(4):765-9
pubmed: 25109955
Nat Rev Drug Discov. 2012 Nov;11(11):873-86
pubmed: 23060265
N Engl J Med. 2019 Jul 25;381(4):317-327
pubmed: 31157963
Cancer Cell. 2019 Jun 10;35(6):851-867.e7
pubmed: 31185210
Cancer Res. 2006 Jul 1;66(13):6503-11
pubmed: 16818621
Clin Cancer Res. 2021 Oct 1;27(19):5299-5306
pubmed: 34315723
JAMA Otolaryngol Head Neck Surg. 2014 Dec;140(12):1225-36
pubmed: 25068501
Cell. 2010 Jan 22;140(2):209-21
pubmed: 20141835
Pharmacol Res. 2021 Nov;173:105911
pubmed: 34560251
Trends Cancer. 2018 Feb;4(2):110-118
pubmed: 29458961
Lancet Oncol. 2017 Jan;18(1):75-87
pubmed: 27908594
N Engl J Med. 2016 Jul 7;375(1):11-22
pubmed: 27406346
Adv Exp Med Biol. 2019;1188:251-266
pubmed: 31820393
Cancer Discov. 2015 Jul;5(7):752-67
pubmed: 26069190
Cancers (Basel). 2020 Mar 20;12(3):
pubmed: 32245016
Biochem Soc Trans. 2020 Jun 30;48(3):1101-1108
pubmed: 32379297
Mol Cell Proteomics. 2005 Apr;4(4):346-55
pubmed: 15671044
Lancet Oncol. 2018 May;19(5):603-615
pubmed: 29573941
Clin Res Hepatol Gastroenterol. 2021 Sep;45(5):101553
pubmed: 33183998
N Engl J Med. 2017 Aug 10;377(6):523-533
pubmed: 28578601
Nat Commun. 2020 Oct 2;11(1):4946
pubmed: 33009409
Cancer Discov. 2014 May;4(5):538-45
pubmed: 24589925
Nat Commun. 2014 May 29;5:3887
pubmed: 24871328
Nature. 2013 Feb 14;494(7436):251-5
pubmed: 23302800
Ann Surg Oncol. 2006 Aug;13(8):1156-61
pubmed: 16791447
Nat Rev Clin Oncol. 2011 Nov 08;9(4):199-207
pubmed: 22064459
Cancer Discov. 2012 Nov;2(11):1036-47
pubmed: 22915752
Bioinformatics. 2007 Aug 1;23(15):1986-94
pubmed: 17599930
Cancer Cell. 2015 Feb 9;27(2):240-56
pubmed: 25600339
AAPS J. 2021 Mar 7;23(2):39
pubmed: 33677681
Mol Cell Proteomics. 2014 Jul;13(7):1625-43
pubmed: 24777629
Nat Med. 2020 Oct;26(10):1564-1568
pubmed: 33020646
Mol Cancer Ther. 2006 Oct;5(10):2512-21
pubmed: 17041095
N Engl J Med. 2001 Apr 5;344(14):1031-7
pubmed: 11287972
Cell Rep. 2017 Apr 4;19(1):203-217
pubmed: 28380359
Cancer Res. 2014 Feb 1;74(3):818-28
pubmed: 24346432
Lancet Oncol. 2017 Sep;18(9):1274-1284
pubmed: 28754483
Nat Rev Clin Oncol. 2019 Feb;16(2):81-104
pubmed: 30356138
Nature. 2017 Jun 15;546(7658):431-435
pubmed: 28607484
Lancet. 2012 Jul 28;380(9839):358-65
pubmed: 22735384
Semin Oncol. 2016 Aug;43(4):476-83
pubmed: 27663479
Oncotarget. 2019 May 28;10(37):3533-3546
pubmed: 31191824
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
Expert Rev Mol Med. 2005 Mar 15;7(4):1-20
pubmed: 15836799
Mol Oncol. 2015 May;9(5):951-9
pubmed: 25888066
Biostatistics. 2019 Apr 1;20(2):273-286
pubmed: 29394327
N Engl J Med. 2014 Nov 13;371(20):1877-88
pubmed: 25265492
Cell. 2012 Apr 13;149(2):307-21
pubmed: 22500798
Adv Exp Med Biol. 2019;1188:1-19
pubmed: 31820380
Adv Exp Med Biol. 2019;1188:21-30
pubmed: 31820381
Nat Rev Cancer. 2022 Jun;22(6):323-339
pubmed: 35264777
JAMA Oncol. 2017 Mar 01;3(3):382-390
pubmed: 28033447